Abstract

▼Tigecycline (pronounced tie-ge-sigh-cleen; Tygacil – Wyeth) is a broad-spectrum antibacterial and the first glycylcycline to be marketed in the UK. It is active against certain resistant bacteria, including meticillin-resistant Staphylococcus aureus (MRSA) and bacteria that produce extended-spectrum β-lactamase (ESBL).1^, 2 Tigecycline is licensed for intravenous treatment of adults with complicated skin and soft tissue infections, and complicated intra-abdominal infections.1 We review tigecycline and assess its place for these infections.